GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocugen Inc (MEX:OCGN) » Definitions » YoY EBITDA Growth

Ocugen (MEX:OCGN) YoY EBITDA Growth : -7.57% (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Ocugen YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Ocugen's YoY EBITDA Growth for the quarter that ended in Sep. 2024 was -7.57%.

Ocugen's EBITDA per Share for the three months ended in Sep. 2024 was MXN-0.90.

Ocugen YoY EBITDA Growth Historical Data

The historical data trend for Ocugen's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocugen YoY EBITDA Growth Chart

Ocugen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 96.90 85.11 -63.35 -32.37 44.04

Ocugen Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 61.01 69.95 45.59 37.00 -7.57

Ocugen YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Ocugen's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (A: Dec. 2023 )
=(EBITDA per Share (A: Dec. 2023 )-EBITDA per Share (A: Dec. 2022 ))/ | EBITDA per Share (A: Dec. 2022 ) |
=(-4.504--8.048)/ | -8.048 |
=44.04 %

Ocugen's YoY EBITDA Growth for the quarter that ended in Sep. 2024 is calculated as:

YoY EBITDA Growth (Q: Sep. 2024 )
=(EBITDA per Share (Q: Sep. 2024 )-EBITDA per Share (Q: Sep. 2023 )) / | EBITDA per Share (Q: Sep. 2023 )) |
=(-0.895--0.832)/ | -0.832 |
=-7.57 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ocugen YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Ocugen's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Ocugen Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocugen Inc (MEX:OCGN) » Definitions » YoY EBITDA Growth
Comparable Companies
SGMO BDTX NYMXF KPTI ABEO ALDX RLMD HOWL MIRO GMDA OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
OCGN:USA 2H51:Germany
Address
11 Great Valley Parkway, Malvern, PA, USA, 19355
Website
https://www.ocugen.com
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").